Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Waste Management, Inc. (WM) Price & Performance

Cytokinetics IncTrade
Waste Management, Inc.Trade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Waste Management, Inc. — how do they compare? Cytokinetics Inc trades at $76.53 (market cap $10.63B), while Waste Management, Inc. trades at $227.36 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 8.5× Cytokinetics Inc's market cap, and Waste Management, Inc. pays a 1.56% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKWM
Market Cap
$10.63B$90.68B
Sector
TechnologyIndustrials
52-Week High
$87.26$246.51
52-Week Low
$34.31$196.77
Enterprise Value
$10.74B$113.47B
Dividend Yield
1.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Waste Management, Inc.

WM trades at $226.6, down 0.47% over 24 hours, with a bullish technical signal and support near $226. The stock shows strong profitability with a 40.6% gross margin and 11.12% net margin, though its P/E of 59.74 is elevated. Recent Q2 2026 earnings beat expectations at $2.02 per share, and analyst consensus is a buy with a $263.43 price target. Cash flow from operations grew to $6.04B in 2025, but net cash flow was negative $190M due to investments.

Outlook is positive with revenue growth and margin stability, but risks include high valuation and debt levels. The stock offers upside to the consensus target, supported by institutional confidence and consistent earnings beats, though investors should monitor volume trends and interest rate impacts on borrowing costs.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Waste Management, Inc.

Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.

Read more on WM